FBLG
FibroBiologics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.80
+2.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$11.98M
MomentumView details →
1D Return
+2.27%
YTD Return
−58.89%
RSI (14)
67.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$11.98M
RSI (14)
67.3
MomentumView details →
1D Return
+2.27%
YTD Return
−58.89%
SummaryUpdated Jun 1, 2026
FibroBiologics, Inc. (NASDAQ:FBLG) is a clinical-stage biotechnology company founded in 2021 and headquartered in Houston, Texas. The company went public in February 2024 and focuses on developing innovative cell therapy treatments using fibroblasts, a type of connective tissue cell. As a pre-revenue biotech firm, FibroBiologics is currently advancing multiple therapeutic candidates through clinical trials, targeting conditions ranging from spinal disc degeneration to multiple sclerosis and cancer treatment.
Similar companies
Latest newsMore news →
FibroBiologics released the third batch of its CYWC628 drug product and shipped it to Australia to support its ongoing Phase 1/2 clinical trial for diabetic foot ulcers.8d agoFibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of its Board of Directors, effective August 20, 2026.12d agoFibroBiologics completed manufacturing of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial in patients with diabetic foot ulcers.59d ago